Abbott Laboratories (ABT) return on equity (ROE)

Return on equity · fiscal 2025
12.5%

Abbott Laboratories (ABT) earned a return on equity of 12.5% in fiscal 2025 (the year ended December 31, 2025). That is 15.6 percentage points lower than the 28.1% of fiscal 2024. Figures as of 17 Nov 2026, 21:50 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
12.5%
Change on fiscal 2024
−15.6 pts
Highest on record
28.1%fiscal 2024
Lowest on record
1.5%fiscal 2017
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Abbott Laboratories return on equity (ROE), in more detail

Across the 19 fiscal years on record (2007–2025), the highest was 28.1% in fiscal 2024 and the lowest 1.5% in fiscal 2017. The fiscal 2025 figure is higher than in 33% of the 18 earlier fiscal years on record, whose median is 19.1%.

History · 19 fiscal years

Return on equity by fiscal year

Abbott Laboratories return on equity (ROE), year by year

Abbott Laboratories (ABT) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202512.5% 15.6 pts down
202428.1% 13.3 pts up
202314.8% 4.1 pts down
202218.9% 0.9 pts down
202119.8% 6.0 pts up
202013.7% 1.9 pts up
201911.9% 4.1 pts up
20187.8% 6.2 pts up
20171.5% 5.3 pts down
20166.8% 14.0 pts down
201520.9% 10.2 pts up
201410.6% 0.4 pts up
201310.2% 12.1 pts down
201222.3% 3.0 pts up
201119.3% 1.1 pts down
201020.4% 4.4 pts down
200924.8% 3.1 pts down
200827.9% 7.6 pts up
200720.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Abbott Laboratories and comparable companies
CompanyReturn on equityFiscal year
Gilead Sciences GILD37.5%2025
Abbott Laboratories ABT12.5%2025
Novo Nordisk NVO52.8%2025
Pfizer PFE9.0%2025
Danaher DHR6.9%2025
Intuitive Surgical ISRG16.0%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on ABT

Abbott Laboratories, figure by figure

Abbott Laboratories (ABT) overview: price, valuation and scorecardAll health care companies by market value

Abbott Laboratories return on equity (ROE): questions and answers

What is Abbott Laboratories's return on equity?

Abbott Laboratories (ABT) earned a return on equity of 12.5% in fiscal 2025 (the year ended December 31, 2025). That is 15.6 percentage points lower than the 28.1% of fiscal 2024.

Is Abbott Laboratories's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 33% of the 18 earlier fiscal years on record, whose median is 19.1%.

What are the highest and lowest return on equity figures on record for Abbott Laboratories?

Across the 19 fiscal years on record (2007–2025), the highest was 28.1% in fiscal 2024 and the lowest 1.5% in fiscal 2017.

How is Abbott Laboratories's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Abbott Laboratories (ABT) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/ABT/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.